Globeflex Capital’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Globeflex Capital’s Portfolio OREX Stock Details OREX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-62,214	Closed	-$350K	–	584
2016 Q1	$350K	Buy	62,214 +32,714	+111%	+$425K	0.09%	271
2015 Q4	$507K	Buy	+29,500	New	+$703K	0.14%	225

Other funds holding OREX

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

Tiverton Asset Management Wilimington, Delaware $2.88B AUM 5.6% 1-Year Est. Return

Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Globeflex Capital's OREX Position: Q2 2016 in Review

Globeflex Capital sold out of Orexigen Therapeutics, Inc. (OREX) in Q2 2016, closing a stake of 62,214 shares — an estimated $350K sold.

Globeflex Capital first reported a position in OREX in Q4 2015 and held it in 2 quarters. The position peaked at $507K in Q4 2015. 73 funds tracked by Wall St. Rank hold OREX as of Q2 2016.

Globeflex Capital reported no remaining Orexigen Therapeutics, Inc. position as of Q2 2016 after selling out during the quarter.
Globeflex Capital sold 62,214 Orexigen Therapeutics, Inc. shares in Q2 2016, an estimated $350K.
Globeflex Capital first reported a position in Orexigen Therapeutics, Inc. in Q4 2015 and held it in 2 quarters.
Globeflex Capital's Orexigen Therapeutics, Inc. position peaked at $507K in Q4 2015.
73 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q2 2016.

Based on Globeflex Capital's 13F filing for Q2 2016, filed 10 Aug 2016.